Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Retained Earnings (2017 - 2025)

Aclaris Therapeutics has reported Retained Earnings over the past 9 years, most recently at -$967.8 million for Q4 2025.

  • Quarterly results put Retained Earnings at -$967.8 million for Q4 2025, down 7.19% from a year ago — trailing twelve months through Dec 2025 was -$967.8 million (down 7.19% YoY), and the annual figure for FY2025 was -$967.8 million, down 7.19%.
  • Retained Earnings for Q4 2025 was -$967.8 million at Aclaris Therapeutics, down from -$948.0 million in the prior quarter.
  • Over the last five years, Retained Earnings for ACRS hit a ceiling of $482000.0 in Q2 2025 and a floor of -$967.8 million in Q4 2025.
  • Median Retained Earnings over the past 5 years was -$634.4 million (2022), compared with a mean of -$466.5 million.
  • Biggest five-year swings in Retained Earnings: tumbled 21823233.33% in 2022 and later skyrocketed 100.06% in 2025.
  • Aclaris Therapeutics' Retained Earnings stood at -$224000.0 in 2021, then plummeted by 304504.91% to -$682.3 million in 2022, then dropped by 12.97% to -$770.8 million in 2023, then dropped by 17.13% to -$902.9 million in 2024, then decreased by 7.19% to -$967.8 million in 2025.
  • The last three reported values for Retained Earnings were -$967.8 million (Q4 2025), -$948.0 million (Q3 2025), and $482000.0 (Q2 2025) per Business Quant data.